[1] World Health Organization. Hepatitis B[EB/OL].(2014-07)[2015-04-02]. http://www. who. int/mediacentre/factsheets/fs204/en/.
|
[2] FAN R,SUN J,HOU JL,et al. Antiviral therapy for chronic hepatitis B:Current status and perspectives[J]. J Clin Heptal,2016,32(11):2029-2032.(in Chinese)樊蓉,孙剑,侯金林,等.慢性乙型肝炎抗病毒治疗现状及展望[J].临床肝胆病杂志,2016,32(11):2029-2032.
|
[3] CHOTIYAPUTTA W,HONGTHANAKORN C,OBERHELMAN K,et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs[J]. J Viral Hepat,2012,19(3):205-212.
|
[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[5] WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[J/OL]. Geneva:World Health Organization,2015.
|
[6] LOCARNINI S,HATZAKIS A,CHEN DS,et al. Strategies to control hepatitis B:Public policy,epidemiology,vaccine and drugs[J]. J Hepatol,2015,62(1 Suppl):s76-s86.
|
[7] HONGTHANAKORN C,CHOTIYAPUTTA W,OBERHELMAN K,et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice[J]. Hepatology,2011,53(6):1854-1863.
|
[8] HA NB,HA NB,GARCIA RT,et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B[J]. Dig Dis Sci,2011,56(8):2423-2431.
|
[9] KAMEZAKI H,KANDA T,WU S,et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus:Vvirological breakthrough is also dependent on adherence to medication[J].Scand J Gastroenterol,2011,46(9):1111-1117.
|
[10] PENG J,YIN J,CAI SH,et al. Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients:results from a 1-year follow-up study[J]. Patient Prefer Adherence,2015,9:41-45.
|
[11] LIEVELD FI,van VLERKEN LG,SIERSEMA PD,et al. Patient adherence to antiviral treatment for chronic hepatitis B and C:a systematic review[J]. Ann Hepatol,2013,12(3):380-391.
|
[12] HAMILTON GA. Measuring adherence in a hypertension clinical trial[J]. Eur J Cardiovasc Nurs,2003,2(3):219-228.
|
[13] XU WH,WANG Q,LIANG WX. Reliability and validity of Morisky Questionnaire in measurement of the compliance with hypertensive medications[J]. Chin J Prev Contr Chron Non-commun Dis,2007,15(5):424-426.(in Chinese)许卫华,王奇,梁伟雄. Morisky问卷测量高血压患者服药依从性的信度和效度评价[J].中国慢性病预防与控制,2007,15(5):424-426.
|
[14] LAI SL. Methods for clinical research based on integrated traditional Chinese and Western medicine[M]. Beijing:Science Press,2003:100.(in Chinese)赖世隆.中西医结合临床科研方法[M].北京:科学出版社,2003:100.
|
[15] OSTERBERG L,BLASCHKE T. Adherence to medication[J].N Engl J Med,2005,353(5):487-497.
|
[16] ZHANG JM. Analysis of compliance with nucleoglycan therapy in patients with chronic hepatitis B[J]. J Aerospace Med,2015,26(4):431-432.(in Chinese)张建明.慢性乙肝患者对核甘类药物治疗的依从性分析[J].航空航天医学杂志,2015,26(4):431-432.
|
[17] LI GJ,ZOU HH,XIU ZL,et al. Multiple regression analysis of factors related to compliance with antiviral therapy in patients with hepatitis B[J]. China Mod Doct,2010,48(28):32-33.(in Chinese)李国军,邹何慧,修自力,等.乙型肝炎抗病毒治疗依从性相关因素多元回归分析[J].中国现代医生,2010,48(28):32-33.
|
[18] ZHU CH,WU YK,LI XY,et al. Compliance status and influencing factors of patients with chronic HBV infection in longterm follow-up cohort[J]. Guangdong Med,2016,37(23):3578-3582.(in Chinese)朱昌浩,吴元凯,李向永,等.慢性HBV感染者长期随访队列患者依从性现状及其影响因素[J].广东医学,2016,37(23):3578-3582.
|
[19] ZHAO Y,ZHANG BP,ZHANG GS,et al. Influencing factors for medication compliance with nucleoside drugs in patients with chronic hepatitis B:A logistic regression analysis[J].Chin J Integr Tradit West Med Liver Dis,2013,23(5):309-311.(in Chinese)赵艳,张伯鹏,张国顺.慢性乙型肝炎核苷类药物治疗依从性影响因素Logistic回归分析[J].中西医结合肝病杂志,2013,23(5):309-311.
|
[20] CHEN JE. Causes influencing compliance with antiviral therapy in patients with hepatitis B and related nursing strategies[J]. Chin J Clin Ration Drug Use,2011,4(29):88-89.(in Chinese)陈菊娥.影响乙肝患者抗病毒治疗依从性的原因分析及护理对策研究[J].临床合理用药杂志,2011,4(29):88-89.
|
[21] POLIS S,ZABLOTSKA-MANOS I,ZEKRY A,et al. Adherence to hepatitis B antiviral therapy:A qualitative study[J].Gastroenterol Nurs,2017,40(3):239-246.
|
[22] XU MM,CHEN Y. Current research on adherence to antiviral therapy in patients with chronic hepatitis B[J]. J Clin Heptal,2015,31(10):1735-1739.(in Chinese)徐曼曼,陈煜.慢性乙型肝炎患者抗病毒治疗依从性的研究现状[J].临床肝胆病杂志,2015,31(10):1735-1739.
|
[23] LUO KX. Hepatitis B basic biology and clinical science[M].2nd Version. Beijing:People’s medical publishing house,2001:226-227.(in Chinese)骆抗先.乙型肝炎基础和临床[M]. 2版.北京:人民卫生出版社,2001:226-227.
|
[24] SHA L,XU Q,HUA L,et al. Analysis of the relationship between treatment compliance,self-efficacy and social support in patients with chronic hepatitis B[J]. Chin J Modern Nurs,2014,20(32):4075-4078.(in Chinese)沙莉,许勤,华琳,等.慢性乙型肝炎患者治疗依从性与自我效能和社会支持的相关性分析[J].中华现代护理杂志,2014,20(32):4075-4078.
|
[25] GUO QF,TIAN YW,SUI J. Effect of We Chat on compliance of oral antiviral therapy in patients with hepatitis B[J]. Contemporary Nurs(mid-issue),2017,4:128-129.(in Chinese)郭琴芳,谭友文,眭静.微信在乙肝患者口服抗病毒药治疗依从性中的效果[J].当代护士(中旬刊),2017,4:128-129.
|
[26] XU LH. Effects of self-efficacy on compliance,self-management and cognition of antiviral therapy in patients with chronic hepatitis B[J]. Chin Foreign Medi Res,2018,16(1):169-170.(in Chinese)许丽红.自我效能对慢性乙肝患者抗病毒治疗依从性、自我管理能力及认知程度的影响分析[J].中外医学研究,2018,16(1):169-170.
|
[27] ZHAO M. Investigation and analysis of hepatitis B knowledge and treatment compliance in patients with chronic hepatitis B[J]. J Clin Nursing’s Pract,2018,3(27):164.(in Chinese)赵梅.慢性乙型肝炎患者对乙肝知识认知情况及治疗依从性的调查分析[J].实用临床护理学杂志,2018,3(27):164.
|
[28] CHOTIYAPUTTA W,PETERSON C,DITAH FA,et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B[J]. J Hepatol,2011,54(1):12-18.
|